Light the Way™

Current approaches often rely on signals that scale with disease burden. Instead, we profile the host response as a leading indicator to disease development via Liquid Biopsy.

By determining an individual's proteotype, we aim to predict treatment response before a patient is prescribed a treatment (a drug or surgery)

By tracking an individual's proteotype, we provide a minimally invasive approach to monitor on-treatment response, such as acquired resistance to treatment, with the potential to impact dosage and efficacy.